- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02614846
Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
November 22, 2015 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura
This study evaluates the safety and efficacy of 6 weeks dosing Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura Patients.
All of the subjects in this study receive Hetrombopag.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
29
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yu Hu, Ph.D
- Email: dr_huyu@126.com
Study Contact Backup
- Name: Heng Mei, Ph.D
- Email: mayheng@126.com
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430022
- Recruiting
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
Contact:
- Yu Hu, Ph.D
- Email: dr_huyu@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Inclusion Criteria:
- Confirmed diagnosis of chronic ITP,a peripheral blood smear or bone marrow examination should support the diagnosis of ITP with no evidence of other causes of thrombocytopenia.
- Patients had a platelet count of less than 30,000/µL both in the screening period and baseline.
- Subjects who are refractory or have relapsed after at least one prior ITP therapy.
- Previous therapy for ITP including rescue must have been completed at least 2 weeks prior to randomization.
- Subjects treated with maintenance immunosuppressive therapy must be receiving a dose that has been stable for at least 1 month.
- A complete blood count (CBC), within the reference range, with the following exceptions.
- Platelets <30×109/L is required for inclusion .
- Hemoglobin: females and males 10.0 g/dl are eligible for inclusion.
Absolute neutrophil count (ANC) ≥1500/µL (1.5×109/L) is required for inclusion.
7.PT result no exceed normal by more than ±3s,APTT result no exceed normal by more than ±10s.
8.Female subjects have a negative result with HCG testing in the screening period and baseline.
Exclusion Criteria:
- Patients with any prior history of arterial or venous thrombosis,or diagnosis as Thrombophilia.
- Subjects diagnosed with tumor.
- Have pre-existing cardiac disease within the last 3 months.No arrhythmia known to increase the risk of thrombolic events (e.g. atrial fibrillation), or patients with a Corrected QT interval (QTc) >450msec or QTc >480 for patients with a Bundle Branch Block.
- Female subjects who are nursing or pregnant at screening or pre-dose on baseline.
- Treatment with thrombopoietin or an investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
- Treatment with Rituximab or Splenectomy within the lat 6 months.
- Subjects who have previously received eltrombopag or any other thrombopoietin receptor agonist within 30 days or five half-lives (whichever is longer).
- Subject has consumed aspirin, aspirin-containing compounds, salicylates, anticoagulants, quinine or non-steroidal anti-inflammatories (NSAIDs) for >3 consecutive days within 2 weeks of the study start and until the end of the study.
- Any laboratory or clinical evidence for HIV infection.Any clinical history for hepatitis C infection; chronic hepatitis B infection; or any evidence for active hepatitis at the time of subject screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Hetrombopag Olamine
All the subjects receive 6 weeks Hetrombopag Olamine dosing, 5mg for the first 2 weeks, 2.5mg or 7.5mg for the last 4 weeks according to the PLT counting.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of subjects with adverse events as a measure of safety and tolerability.
Time Frame: From Day 1 to Day 70.
|
From Day 1 to Day 70.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2015
Primary Completion (ANTICIPATED)
March 1, 2016
Study Registration Dates
First Submitted
November 19, 2015
First Submitted That Met QC Criteria
November 22, 2015
First Posted (ESTIMATE)
November 25, 2015
Study Record Updates
Last Update Posted (ESTIMATE)
November 25, 2015
Last Update Submitted That Met QC Criteria
November 22, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Autoimmune Diseases
- Hematologic Diseases
- Hemorrhage
- Hemorrhagic Disorders
- Blood Coagulation Disorders
- Skin Manifestations
- Thrombocytopenia
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombocytopenic, Idiopathic
Other Study ID Numbers
- HR-TPO- Ie-ITP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Idiopathic Thrombocytopenic Purpura
-
University Hospital, BordeauxCompletedChronic Idiopathic Thrombocytopenic Purpura | Congenital Thrombocytopenia
-
GlaxoSmithKlineCompletedChronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, IdiopathicJapan
-
Eisai Inc.CompletedChronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, IdiopathicUnited States
-
Bio Products LaboratoryCompletedChronic Idiopathic Thrombocytopenic PurpuraUnited States, India, Argentina
-
Eisai Inc.CompletedPurpura, Thrombocytopenic, Idiopathic | Chronic Thrombocytopenia | Acute Idiopathic Thrombocytopenic PurpuraNetherlands
-
Protalex, Inc.TerminatedPhase I Safety and Tolerability Study of Staphylococcal Protein A in Adult Patients With Chronic ITPIdiopathic Thrombocytopenic Purpura (ITP)Australia, New Zealand
-
CSL LimitedCompletedIdiopathic Thrombocytopenic Purpura (ITP)Australia
-
University Hospital, AngersMinistry of Health, FranceUnknownAcute Idiopathic Thrombocytopenic PurpuraFrance
-
Mahidol UniversityRamathibodi HospitalCompletedChronic Idiopathic Thrombocytopenic Purpura | Helicobacter Pylori InfectionThailand
-
AmgenCompletedThrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenic PurpuraUnited States, Canada, Australia
Clinical Trials on Hetrombopag Olamine
-
Jiangsu HengRui Medicine Co., Ltd.UnknownPurpura, Thrombocytopenic, IdiopathicChina
-
RenJi HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingChemotherapy-Induced Thrombocytopenia
-
Jiangsu HengRui Medicine Co., Ltd.CompletedImmune ThrombocytopeniaChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.CompletedIdiopathic Thrombocytopenic PurpuraChina
-
Tongji HospitalNot yet recruitingMyelodysplastic Syndromes
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Huazhong University of Science and TechnologyRecruitingMalignant Tumors of the Digestive System | TrombocitopeniaChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedSevere Aplastic AnemiaChina